Financial Times/Deloitte Global Pharmaceutical & Biotechnology Conference
9-10 November, 2017 | The Landmark Hotel | London
This industry-leading event brings together life sciences companies, their health industry counterparts, and emerging new industry entrants to review the key challenges facing the industry. The event will also discuss business models and transformation strategies that will be needed to survive and thrive in this new era of unprecedented disruption and uncertainty.
- Register Now
- Deloitte sessions
- Key topics featured at the FT Pharma Bio conference
- Who is speaking?
- Join the Conversation
As old world certainties regarding payments, products and patients are swept away in a tidal wave of pricing pressures, growing geopolitical uncertainties and the new world realities of value, data and outcomes, life sciences companies will need to find new ‘ways to play’ if they are to adapt and compete in the new health economy which is emerging.
Key topics featured at the FT Pharma Bio conference
- ‘Way to Play’: Embracing strategic opportunities in the new health economy
- Getting the big picture: Geopolitical and economic risk-what lies ahead?
- Adopting open innovation-location, strategies, risks
- The trouble with Alzheimer’s: transforming treatment, prevention and care
- Social Prescribing - the next big thing?
- Disrupt or be disrupted: The big digital debate
Who is speaking?
- Richard Mason, Head of Johnson & Johnson Innovation, EMEA
- Andy Schmeltz, Senior Vice President, Patient & Health Impact, Pfizer
- Rod MacKenzie, Executive Vice President, Chief Development Officer, Pfizer
- Stephen Moran, Global Head of Strategy, Novartis
- Flemming Ornskov, Chief Executive Officer, Shire
- Bélén Garijo, Member of the Board and CEO, Healthcare, The Merck Group
- Simon Stevens, Chief Executive Officer, NHS England
- Bahija Jallal, Executive Vice President, AstraZeneca and Head, MedImmune
- David Hodgson, Global Life Sciences & Health Care Risk Advisory Leader, Deloitte
- Adam Hill, Chief Medical Officer, McLaren Applied Technologies